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may be chronically impaired from recurrent infection (even 
in the absence of overt diarrhoea), it may also prove 
beneficial when the intestinal flora and architecture are 
normal. T he potential for ORS to improve the absorption or 
adsorption of other orally administered pharmaceuticals 
should also be examined.
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Galactosaemia
Sir—-Allen (Jan 14, p 128) claims that in our commentary 
(Nov 5) p 1242) we foiled to take note of the importance of 
prospective studies o f newly diagnosed cases of 
galactosaemia. W e focused on the outcome of retrospective 
studies because no prospective studies have been published. 
Allen cites an abstract o f his own small uncontrolled 
retrospective study to support the value o f neonatal 
screening. Unfortunately he cites the world-wide study by 
Waggoner and colleagues1 that omits the most convincing 
evidence that early treatment has little effect on long-term 
outcom e—namely, that from sib pairs. The results in the 
reference we cited and from earlier studies of sibs2 indicate 
that the long-term outcome of sibs of known galactosaemics 
who were usually treated from birth was no different from 
that of the index case who had been started on treatment 
much later, many not before 3 months of age. Screened 
patients might be expected to have fewer neonatal 
complications, although the timing of the screening test is 
critical. In the U K , screening tests are done between 6 and
14 days, and a survey’ has shown no difference in neonatal 
complications in the screened and unscreened groups,
In our final paragraph we emphasise the importance of 
carefully planned prospective studies of patient outcome. We 
also mentioned the contribution that a register could make 
in collecting longitudinal data, and in this respect we are 
pleased to report that a U K  galactosaemia register has now  
been set up.
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Frequency of familial melanoma and MLM2 
gene
Sir—Battistutta and colleagues (Dec 10, p 1607) report that 
die penetrance of the familial melanoma gene M LM 2  is 
rising, with a decrease in median age of onset of melanoma. 
They base this conclusion on the Finding that subsequent 
birth cohorts of mutated M LM 2  carriers have a higher 
cumulative risk of melanoma. The study population 
consisted of 18 kindreds from Queensland, Australia^ who 
were previously linked to the putative M LM 2  gene on 
chromosome 9p. Gene carriers were identified by haplotype 
analysis. Where data were unavailable for family members, 
carrier status was imputed while assuming, for example, no 
new mutations among founders. By age 40, the cumulative 
risk among carriers was 36%. Among carriers born before 
1900 this risk was only 1 1% whereas carriers born after 1940 
had a risk of 64%. The expected age of onset was 45 years in 
the oldest birth cohort and 21 years in the youngest cohort 
(Battistutta and co-workers do not explain how they 
calculated this), They do not say how many carriers were 
born before 1900 but according to the graph only 5 patients 
died from melanoma in the oldest cohort. Battistutta and 
colleagues discuss some potential caveats as alternative 
explanations for their results, They argue that an earlier 
diagnosis of more recently affected cases is not likely because 
the increasing trend in melanoma is largely attributable to 
invasive lesions, A differential case-ascertainment across 
cohorts was thought to be unlikely because o f the 
comprehensive search of death certificates and hospital 
records.
In my opinion Battistutta and colleagues fail to mention 
the most important possible bias, It is known that hereditary 
cancers are often diagnosed at an early age. Therefore, in the 
search for genes (linkage analyses) in hereditary subtypes of 
common cancers one usually focuses on families with early- 
onset disease. It is quite possible that the 18 Australian 
kindreds were selected originally for linkage analyses because 
of the presence of one or more young melanoma patients. 
Probably all these young cases belong to the youngest birth 
cohort because of the availability of hospital and cancer 
registry records. It is very likely that the relatives of these 
probands have a smaller risk of melanoma and that they are 
diagnosed, on average, at older ages than the probands 
themselves; this pattern is known as regression towards the 
mean,1 Thus, before it is concluded that the penetrance of 
the M LM 2  gene is increasing it is important to know on 
which criteria the 18 familial melanoma kindreds were 
selected.
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Sir— Battistutta and colleagues construct life-table analyses 
by birth cohort for family members carrying M LM 2  and 
conclude that “these data support the notion that 
phenotypic penetrance of the M LM 2  gene is increasing”. 
The analysis as reported, however, seems to neglect the 
selection process by which these families were chosen for the 
original genetic linkage study; this can lead to serious bias in 
the penetrance estimates. To be informative in a linkage 
study, the families are chosen to contain many cases since 
such families provide the most convincing evidence of 
inherited susceptibility (especially in areas with high 
background rates of disease). Furthermore, the cases leading 
to the selection of a family for a linkage study tend to be
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